Silence Therapeutics PLC Hiring of Chief Operating Officer
01 June 2017 - 4:00PM
RNS Non-Regulatory
TIDMSLN
Silence Therapeutics PLC
01 June 2017
Hiring of Chief Operating Officer
1 June 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery, and development of novel RNA
therapeutics for the treatment of serious diseases with unmet
medical need, announces the hiring of Torsten Hoffmann as Chief
Operating Officer, reporting directly to Ali Mortazavi, Chief
Executive Officer. This is not a plc board appointment.
Torsten is joining Silence from Proteros biostructures where he
served as Chief Scientific Officer and Managing Director from July
2015, and before then as Chief Scientific Officer and Executive
Vice President at Zealand Pharma from July 2013. Prior to that, he
spent 16 years at Roche in roles of increasing responsibility up to
Site Head of Medicinal Chemistry, and Head of the Global Roche
Postdoc fellowship program. Torsten is the lead inventor of
netupitant, discovered at Roche and approved by the FDA as
Akynzeo(c) in 2014.
Torsten has a Ph.D. in Chemistry from the ETH Zürich,
Switzerland, which was followed by a role as research associate
with Professor Richard A. Lerner at the Scripps Research Institute
in La Jolla, California. He has authored more than 85 publications,
patent applications and published conference reports, has served on
advisory boards, and his awards include the Feodor Lynen award and
fellowship from the Alexander von Humboldt Foundation, Germany.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics,
commented:
"I am delighted that Torsten has joined Silence at this pivotal
time for the company. As we continue to make progress with our new
GalNAc-based platform, Torsten brings an experienced rigour to our
operations with his knowledge from target selection through to
clinical trials. I have been impressed with his energy and the way
that he has quickly formed a close working relationship with our
Chief Scientific Officer, Dmitry Samarsky. As a consultant, he has
already enabled us to drive efficiency through outsourcing certain
activities and he will add further immediate benefits in the field
of gene target selection and novel RNA therapeutics, helping to
further differentiate Silence in delivering high quality medicines
for better patients' lives."
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20
Ali Mortazavi, Chief Executive 3457 6900
Officer
David Ellam, Chief Financial Officer
Canaccord Genuity Limited (Nominated Tel: +44 (0)20
Adviser and Joint Broker) 7523 8350
Henry Fitzgerald-O'Connor/Emma
Gabriel
Peel Hunt LLP (Joint Broker) Tel: +44 (0)20
James Steel/Oliver Jackson 7418 8900
Media Enquiries: Tel: +44 (0) 20
FTI Consulting 3727 1000
Simon Conway/Brett Pollard/Stephanie
Cuthbert
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by
harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Our proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using our enabling delivery
systems, we have achieved an additional level of specificity by
delivering our therapeutic RNA molecules exclusively to target
cells. Silence's proprietary RNA chemistries and delivery systems
are designed to improve the stability of our molecules and enhance
effective delivery to target cells, providing a powerful modular
technology well suited to tackle life-threatening diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASDEFMFFWSEDI
(END) Dow Jones Newswires
June 01, 2017 02:00 ET (06:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024